Related references
Note: Only part of the references are listed.Universal standardization for dual X-ray absorptiometry: Patient and phantom cross-calibration results
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Steven Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo:: Results from the EUROFORS study
Christian Graeff et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis
J. C. Gallagher et al.
BONE (2006)
Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study
Silvano Adami et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Characterization of patients with an inadequate clinical outcome from osteoporosis therapy:: the Observational Study of Severe Osteoporosis (OSSO)
F. Jakob et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2006)
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis
Yanfei L. Ma et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
The use of parathyroid hormone in the treatment of osteoporosis
Monica Girotra et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2006)
Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis
DC Bauer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Update of current therapeutic options for the treatment of postmenopausal osteoporosis
S Epstein
CLINICAL THERAPEUTICS (2006)
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
R Prince et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Daily and cyclic parathyroid hormone in women receiving alendronate
F Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
MR McClung et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women
K Uusi-Rasi et al.
BONE (2005)
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
B Ettinger et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography
B Borah et al.
BONE (2004)
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2004)
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
R Lindsay et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
JR Zanchetta et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis
R Marcus et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
E Orwoll et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
YB Jiang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2002)
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis:: A paired biopsy study
DW Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
GY Boivin et al.
BONE (2000)
Share Paper
